FLT3LG and prostate neoplasm: In flt3-L-treated severe combined immunodeficient (SCID) mice, the growth of tumor stabilization and regression of palpable ectopic prostate tumors (TRAMP-C1) cells was more rapid than in flt3-L-treated wild-type mice.